← Back to Search

Selective Serotonin Reuptake Inhibitor

Fluoxetine for Depression

Phase 4

Waitlist Available

Led By Ash Seghal, MD

Research Sponsored by MetroHealth Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial will help to develop a better way to screen for and treat depression in hemodialysis patients.

Eligible Conditions

Depression
Hemodialysis Symptoms

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To determine the impact of directly observed weekly fluoxetine treatment on remission of depression among hemodialysis patients.

Mental Depression

Secondary outcome measures

To examine the responsiveness of the new depression screening instrument to depression treatment.

Side effects data

From 2012 Phase 4 trial • 43 Patients • NCT00245635

Weight Loss

Stomach Pains

Menstrual Cramps

Emotional

Suicidal Behavior

Nightmares

Nausea

Insomnia

Silliness/Feeling too happy

Trouble Sleeping

Lit Paper on Fire

Fatigue

Decreased Appetite

Sweating

Agitated/Restlessness

Dry Mouth

Headache

100%

80%

60%

40%

20%

Study treatment Arm

Placebo

Fluoxetine

Trial Design

1Treatment groups

Experimental Treatment

Group I: Fluoxetine GroupExperimental Treatment1 Intervention

Approximately 96 patients will be enrolled into the intervention (Phase II) over the duration of the entire study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Fluoxetine

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

MetroHealth Medical CenterLead Sponsor

114 Previous Clinical Trials

21,447 Total Patients Enrolled

2 Trials studying Depression

400 Patients Enrolled for Depression

Ash Seghal, MDPrincipal InvestigatorMetroHealth Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any unfilled slots for participants in this research endeavor?

"Affirmative, clinicaltrials.gov displays that this experiment remains open to recruits since it was initially posted on March 1st 2018. The documentation has received its most recent updates on September 27th 2022."

Answered by AI

Have prior experiments explored the application of Fluoxetine?

"Prevalently, 15 clinical trials are assessing the efficacy of Fluoxetine with 2 currently in Phase 3. Of these studies, 20 geographically disparate locations offer patients access to this research medication; notably New Haven, Connecticut."

Answered by AI

What medical indications do healthcare providers typically prescribe Fluoxetine for?

"Fluoxetine has been approved as a viable treatment for myoclonus, unipolar depression and obsessive-compulsive disorder."

Answered by AI

Has the FDA granted licensing to Fluoxetine?

"Fluoxetine has been approved for use, placing it at a safety rating of 3 on the scale. This is due to its Phase 4 status in clinical trials."

Answered by AI

What is the largest patient population involved in this medical experiment?

"Affirmative. Records on clinicaltrials.gov reveal that this research study, which was first made available in March 2018, is currently enrolling participants. The endeavour hopes to recruit approximately 96 patients from a single medical centre."

Answered by AI